Does Trimethylamine N-Oxide (TMAO) predict mortality risk and long-term adverse events in patients with peripheral artery disease?
TMAO levels may help identify high-risk PAD patients who require more aggressive dietary and pharmacologic therapy.
TMAO, a pro-atherogenic metabolite formed by gut microbes, predicts long-term adverse event risk and incremental prognostic value in patients with PAD. These findings point to the potential for TMAO to help improve selection of high-risk PAD patients with or without significant coronary artery disease, who likely need more aggressive and specific dietary and pharmacologic therapy.
Senthong et al. (Mon,) studied this question.